FDA Investigator: Nancy T. Waites

- Nancy T. Waites first started conducting FDA inspections in 2007, with the last inspection in 2015. Over that time, Nancy T. Waites has conducted 17 inspections at 15 companies across 15 sites.

Get Nancy Waites's official FDA inspection documents. Gain valuable insights from their Form 483s and EIRs to ace your next inspection.

Documents

Upon purchase, you will receive an email with a link to immediately download the documents.

FDA 483 Biovex Incorporated, Woburn | 2015

Out-of-stock
Nancy T. Waites
Biologic Form 483

FDA 483 St Luke's Cancer Institute, Kansas City | 2012

Out-of-stock
Nancy T. Waites
Biologic Form 483

FDA 483 St Louis Cord BB & Progenitor Cell Lab, Saint Louis | 2012

Out-of-stock
Nancy T. Waites
Biologic Form 483

FDA 483 Duke University Medical Center Stem Cell Lab., Durham | 2012

Out-of-stock
Nancy T. Waites
Biologic Form 483

FDA 483 Instituto Bioclon, S.A. de C.V., Mexico | 2011

Out-of-stock
Nancy T. Waites
Biologic Form 483

FDA 483 MedImmune Vaccines, Inc, Santa Clara | 2010

Out-of-stock
Nancy T. Waites
Biologic Form 483

FDA 483 Pfizer Ireland Pharmaceuticals, Dublin 22 | 2009

Out-of-stock
Nancy T. Waites
Biologic Form 483

FDA 483 Instituto Bioclon, S.A. de C.V., Mexico | 2009

Out-of-stock
Nancy T. Waites
Biologic Form 483

FDA 483 Baxter Healthcare Corp, Los Angeles | 2008

Out-of-stock
Nancy T. Waites
Biologic Form 483

FDA 483 Grifols Biologicals Inc., Los Angeles | 2008

Out-of-stock
Nancy T. Waites
Biologic Form 483

FDA 483 Zymogenetics,Inc. (a subsidiary of Bristol-Myers Squibb), Seattle | 2007

Out-of-stock
Nancy T. Waites
Biologic Form 483

FDA 483 AbbVie Research Bioresearch Center, Worcester | 2007

Out-of-stock
Nancy T. Waites
Human Drug Form 483